US Stem Cell

US Stem Cell FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of US Stem Cell (USRM) as of Oct 9, 2026 is 10.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 32.18 % — a change of -66.85% (lower).

FCF Conversion

10.67 %

YoY

-66.85%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of US Stem Cell is 2022 10.67 % . FCF Conversion Rate (FCF/EBITDA) of US Stem Cell was 2021 32.18 % . It decreases by -66.85% lower compared to the previous year.

The US Stem Cell FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
51.57 USD
Jan 1, 2016
-4.81 USD
Jan 1, 2017
-35.34 USD
Jan 1, 2018
-27.89 USD
Jan 1, 2019
31.58 USD
Jan 1, 2020
16.57 USD
Jan 1, 2021
32.18 USD
Jan 1, 2022
10.67 USD
The US Stem Cell FCF Conversion history
YEARFCF ConversionYoY
10.67 %-66.85%
32.18 %+94.23%
16.57 %-47.53%
31.58 %-213.22%
-27.89 %-21.08%
-35.34 %+634.52%
-4.81 %-109.33%
51.57 %+4.06%
49.56 %—
Access this data via the Eulerpool API

US Stem Cell Stock analysis

What does US Stem Cell do? US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry. US Stem Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about US Stem Cell stock

FCF Conversion Rate (FCF/EBITDA) of US Stem Cell is 10.67 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of US Stem Cell changed from 32.18 % to 10.67 %, representing a -66.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) US Stem Cell since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s US Stem Cell with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — US Stem Cell

All Key Metrics — US Stem Cell